Last reviewed · How we verify
Trivalent influenza vaccine GSK 138842A — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Trivalent influenza vaccine GSK 138842A (Trivalent influenza vaccine GSK 138842A) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trivalent influenza vaccine GSK 138842A TARGET | Trivalent influenza vaccine GSK 138842A | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trivalent influenza vaccine GSK 138842A CI watch — RSS
- Trivalent influenza vaccine GSK 138842A CI watch — Atom
- Trivalent influenza vaccine GSK 138842A CI watch — JSON
- Trivalent influenza vaccine GSK 138842A alone — RSS
Cite this brief
Drug Landscape (2026). Trivalent influenza vaccine GSK 138842A — Competitive Intelligence Brief. https://druglandscape.com/ci/trivalent-influenza-vaccine-gsk-138842a. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab